|
1
|
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
20.89
|
|
2
|
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
|
Cancer Cell
|
2004
|
2.71
|
|
3
|
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
|
Int J Cancer
|
2002
|
2.12
|
|
4
|
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
|
Clin Colorectal Cancer
|
2008
|
1.89
|
|
5
|
Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
|
Cancer Res
|
2006
|
1.79
|
|
6
|
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
|
Cancer Res
|
2006
|
1.71
|
|
7
|
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer.
|
Lab Invest
|
2002
|
1.57
|
|
8
|
Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer.
|
Clin Cancer Res
|
2002
|
1.44
|
|
9
|
AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.
|
Mol Cancer Ther
|
2009
|
1.39
|
|
10
|
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.
|
Mol Cancer Ther
|
2010
|
1.27
|
|
11
|
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
|
Clin Cancer Res
|
2007
|
1.27
|
|
12
|
Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
|
J Pharmacol Exp Ther
|
2011
|
1.25
|
|
13
|
IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma.
|
J Cell Biochem
|
2004
|
1.15
|
|
14
|
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
|
Cancer Res
|
2010
|
1.08
|
|
15
|
Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin.
|
Clin Exp Metastasis
|
2003
|
1.07
|
|
16
|
Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
|
Cancer Res
|
2006
|
1.04
|
|
17
|
Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth.
|
Mol Cancer Ther
|
2010
|
1.04
|
|
18
|
Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
|
Clin Cancer Res
|
2009
|
0.97
|
|
19
|
Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models.
|
Mol Cancer Res
|
2008
|
0.91
|
|
20
|
Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.
|
Cancer Res
|
2003
|
0.91
|
|
21
|
c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.
|
Clin Exp Metastasis
|
2003
|
0.87
|
|
22
|
Motility is rate-limiting for invasion of bladder carcinoma cell lines.
|
Int J Biochem Cell Biol
|
2002
|
0.87
|
|
23
|
Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis.
|
Bone
|
2010
|
0.84
|
|
24
|
Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models.
|
Neoplasia
|
2013
|
0.83
|
|
25
|
Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.82
|
|
26
|
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
|
J Med Chem
|
2010
|
0.82
|
|
27
|
Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
|
Mol Cancer Ther
|
2009
|
0.82
|
|
28
|
Epitope-specific mechanisms of IGF1R inhibition by ganitumab.
|
PLoS One
|
2013
|
0.82
|
|
29
|
AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
|
Mol Cancer Ther
|
2013
|
0.81
|
|
30
|
Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA).
|
Prostate
|
2004
|
0.81
|
|
31
|
Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model.
|
Nucl Med Biol
|
2013
|
0.80
|
|
32
|
Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.
|
Mol Cancer Ther
|
2009
|
0.80
|
|
33
|
Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer.
|
Mol Cancer
|
2012
|
0.79
|
|
34
|
IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.
|
J Endocrinol
|
2014
|
0.78
|
|
35
|
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.
|
Bioorg Med Chem Lett
|
2011
|
0.78
|
|
36
|
Characterization of 64Cu-DOTA-conatumumab: a PET tracer for in vivo imaging of death receptor 5.
|
J Nucl Med
|
2011
|
0.76
|
|
37
|
AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.
|
J Transl Med
|
2014
|
0.75
|